Rozmán C, Grañena A, Hernandez-Nieto L
Rev Bras Pesqui Med Biol. 1979 Jun;12(2-3):197-206.
A review of the present results of bone-marrow transplantation (B.M.T.) in severe aplastic anaemia is presented. Nowadays, there is little doubt that for patients with severe aplastic anaemia the treatment of choice is the B.M.T. provided always that a suitable donor exists. If the patient is fortunate enough to have a normal identical twin, the syngeneic B.M.T. without immunosuppresive conditioning must be performed. This is usually successful, though in some patients failures can be observed due to probable immunological interference. This can be overcome by a new syngeneic B.M.T. preceded by immunosuppression. The usual type of suitable donors is an HLA-identical (including locus D) sibling (allogeneic B.M.T.). Approximately 50% of patients treated in this way can become long-term survivors. The chief complications causing mortality from the allogeneic B.M.T. are graft rejection and graft-versus-host-disease (G.V.H.D.). In order to reduce the graft rejection rate, transfusions from marrow-donor and relatives prior to the transplantation should be avoided. Other probable factor influencing the final outcome of the allogeneic B.M.T. are the interval diagnosis-transplantation, age of the patient, marrow cell dose, the difference of sex between the donor and the recipients and others. Semi-incompatible and incompatible allogeneic B.M.T. are briefly considered.
本文综述了严重再生障碍性贫血患者骨髓移植(B.M.T.)的当前结果。如今,毫无疑问,对于严重再生障碍性贫血患者,只要有合适的供体,首选治疗方法就是骨髓移植。如果患者有幸拥有同卵双胞胎,必须进行无需免疫抑制预处理的同基因骨髓移植。这通常是成功的,不过在一些患者中,由于可能的免疫干扰会观察到失败情况。这可以通过在免疫抑制后进行新的同基因骨髓移植来克服。合适供体的常见类型是人类白细胞抗原(HLA)匹配(包括D位点)的同胞(异基因骨髓移植)。以这种方式治疗的患者中约50%可成为长期存活者。异基因骨髓移植导致死亡的主要并发症是移植物排斥和移植物抗宿主病(G.V.H.D.)。为了降低移植物排斥率,移植前应避免接受骨髓供体和亲属的输血。影响异基因骨髓移植最终结果的其他可能因素包括诊断到移植的间隔时间、患者年龄、骨髓细胞剂量、供体与受体之间的性别差异等。本文简要讨论了半相合和不相合的异基因骨髓移植。